Kiromic BioPharma, Inc. (NASDAQ:KRBP – Get Free Report)’s share price fell 7.9% on Tuesday . The stock traded as low as $1.08 and last traded at $1.08. 979 shares were traded during mid-day trading, a decline of 51% from the average session volume of 2,009 shares. The stock had previously closed at $1.17.
Kiromic BioPharma Price Performance
The firm has a market cap of $1.52 million, a price-to-earnings ratio of -0.28 and a beta of 1.66. The stock’s fifty day moving average price is $1.20 and its 200-day moving average price is $1.19.
Kiromic BioPharma Company Profile
Kiromic BioPharma, Inc, a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.
Further Reading
- Five stocks we like better than Kiromic BioPharma
- What Are Dividends? Buy the Best Dividend Stocks
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Ride Out The Recession With These Dividend Kings
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- Pros And Cons Of Monthly Dividend Stocks
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
